ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Khorana score for estimating venous thromboembolism risk in patients with cancer

Khorana score for estimating venous thromboembolism risk in patients with cancer
Khorana score
Risk factor Points
Site of primary tumor
Very high risk (stomach, pancreas) 2
High risk (lung, lymphoma, gynecologic, bladder, testicular) 1
All other sites 0
Pre-chemotherapy platelet count ≥350,000/microL 1
Hemoglobin level <10 g/dL or use of ESAs 1
Pre-chemotherapy WBC >11,000/microL 1
BMI ≥35 kg/m2 1
Incidence of VTE based on Khorana score
Khorana score points

Derivation cohort[1]

VTE risk after 2.5 months

Validation cohort[1]

VTE risk after 2.5 months

Independent cohort[2]

VTE risk after 6 months

Patients in phase I trials[3]

VTE risk after 2 months
0 (low) 0.8% 0.3% 1.5% 1.5%
1 to 2 (intermediate) 1.8% 2% 3.8% (1 point); 9.6% (2 points) 4.8%
≥3 (high) 7.1% 6.7% 17.7% 12.9%
The Khorana score was developed from a cohort of 2701 patients with cancer receiving a first course of chemotherapy to predict the cumulative incidence of VTE at 2.5 months[1]. The score was validated in a cohort of 1365 patients, most of whom (91%) had an ECOG performance status of 0 or 1. The score was tested independently in 819 patients with newly diagnosed cancer or cancer progression who had not received chemotherapy within the preceding 3 months to predict the cumulative incidence of VTE at 6 months[2], and in 1415 patients enrolled in phase I clinical trials followed for a median of 2 months[3].
ESAs: erythropoiesis-stimulating agents; WBC: white blood cell; BMI: body mass index; VTE: venous thromboembolism; ECOG: Eastern Cooperative Oncology Group.
References:
  1. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902.
  2. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377.
  3. Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol 2012; 23:1416.
Graphic 73002 Version 6.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟